BofA raises target for Elevance Health stock from USD 460.00 to USD 480.00

Published on 10/01/2026 at 22:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 adjusted EPS reached USD 7.45, above consensus USD 6.21. Elevance Health stock trades at EUR 340.10 on October 1, 2026, while guidance stays at USD 27.00.

Elevance Health, US0367521038, Illustration mit AI erstellt.

Elevance Health (ISIN US0367521038) received a higher BofA Securities price target of USD 480.00 from USD 460.00 on September 11, 2026, while Elevance Health stock was trading at EUR 340.10 at Lang & Schwarz on October 1, 2026 at 10:10 p.m. CEST. The target change gives the insurer a fresh valuation reference ahead of its third-quarter report.

BofA lifts the valuation mark

According to MarketScreener, BofA Securities increased its target from USD 460.00 to USD 480.00 on September 11, 2026. The same report identifies a consensus target of USD 451.38 from 22 analysts, making the new BofA target USD 28.62 above that average.

The valuation call follows a mixed earnings picture. For the second quarter of 2026, Elevance Health reported operating revenue of USD 49.83 billion and adjusted earnings per share of USD 7.45, compared with consensus adjusted earnings per share of USD 6.21, according to Yahoo Finance on September 30, 2026.

Guidance meets medical-cost pressure

Elevance Health reaffirmed fiscal 2026 adjusted earnings guidance of at least USD 27.00 per diluted share and benefit expense ratio guidance of 90.2 percent plus or minus 0.50 percentage points in a September 10, 2026 Form 8-K filed with the SEC. Management also maintained an operating cash flow outlook of at least USD 6.00 billion and pointed to adjusted earnings growth of at least 12.00 percent in fiscal 2027, according to Investing.com on September 10, 2026.

The counterweight is medical-cost pressure in Medicaid and ACA plans. Simply Wall St reported on October 1, 2026, that membership erosion and elevated medical costs could challenge the valuation narrative, despite a 9.76 percent year-to-date share-price return.

Stock trades near its yearly midpoint

At Lang & Schwarz, Elevance Health stock stood at EUR 340.10 on October 1, 2026 at 10:10 p.m. CEST. The primary listing is on the NYSE, where the finance quote showed USD 381.79 at 7:59 p.m. UTC, while the same quote placed the 52-week range at USD 274.84 to USD 436.24 and market capitalization at USD 82.8 billion.